Form 13-F position report

KEZAR LIFE SCIENCES INC

Reported by ORBIMED ADVISORS LLC

KZR CUSIP 49372L100 Manager CIK 0001055951

Reported 1,927,000 shares, unchanged from the prior quarter.

Reported value -4.8%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.03% This manager · Q1 2024
Shares 1,927,000 Quarter-end amount reported
Reported value $1,737,383 Fair value at quarter end
Consecutive quarters held 8 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 9936000
2021-12-31 0
2022-06-30 11743000
2022-09-30 15254000
2022-12-31 32273627
2023-03-31 17099190
2023-06-30 13384350
2023-09-30 6500970
2023-12-31 1825640
2024-03-31 1737383
2024-06-30 1156200
2024-09-30 1489956
2024-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for KEZAR LIFE SCIENCES INC held by ORBIMED ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2024 Reduced 0 -1,927,000 (-100.0%) 0 $0 2025-02-14
Q3 2024 Unchanged 1,927,000 0 (0.0%) 0.03% $1,489,956 2024-11-14
Q2 2024 Unchanged 1,927,000 0 (0.0%) 0.02% $1,156,200 2024-08-14
Q1 2024 Unchanged 1,927,000 0 (0.0%) 0.03% $1,737,383 2024-05-15
Q4 2023 Reduced 1,927,000 -3,536,000 (-64.7%) 0.04% $1,825,640 2024-02-14
Q3 2023 Unchanged 5,463,000 0 (0.0%) 0.14% $6,500,970 2023-11-14
Q2 2023 Unchanged 5,463,000 0 (0.0%) 0.25% $13,384,350 2023-08-14
Q1 2023 Added 5,463,000 +878,678 (19.2%) 0.34% $17,099,190 2023-05-15
Q4 2022 Added 4,584,322 +2,812,622 (158.8%) 0.62% $32,273,627 2023-02-14
Q3 2022 Added 1,771,700 +351,800 (24.8%) 0.29% $15,254,000 2022-11-14
Q2 2022 New 1,419,900 +1,419,900 (0.0%) 0.22% $11,743,000 2022-08-15
Q4 2021 Reduced 0 -1,150,000 (-100.0%) 0 $0 2022-02-14
Q3 2021 Added 1,150,000 +592,809 (106.4%) 0.11% $9,936,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

96 managers reported KEZAR LIFE SCIENCES INC for Q1 2024.

Managers reporting KEZAR LIFE SCIENCES INC in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SUVRETTA CAPITAL MANAGEMENT LLC Unchanged 7,167,591 0 0.24% $6,462,300 17 qtrs
Avidity Partners Management LP Added 5,026,000 +546 0.15% $4,531,442 13 qtrs
BlackRock Inc Reduced 4,616,988 -200,278 < 0.01% $4,162,677 24 qtrs
VANGUARD GROUP INC Added 3,094,224 +30,740 < 0.01% $2,789,753 24 qtrs
SPHERA FUNDS MANAGEMENT LTD Unchanged 2,051,676 0 0.26% $1,849,791 10 qtrs
ORBIMED ADVISORS LLC This report Unchanged 1,927,000 0 0.03% $1,737,383 8 qtrs
ACADIAN ASSET MANAGEMENT LLC Added 1,790,838 +534,203 < 0.01% $1,613,000 5 qtrs
Affinity Asset Advisors LLC New 1,761,778 +1,761,778 0.2% $1,588,419 1 qtr
GEODE CAPITAL MANAGEMENT LLC Added 1,373,689 +19,041 < 0.01% $1,238,643 23 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 1,338,074 +46,155 < 0.01% $1,206,000 19 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 15, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
1,927,000

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.